Quest Diagnostics (0KSX.L) Q3 2025 Earnings Report

Quest Diagnostics reported solid year-over-year revenue growth in QQ3 2025, supported by stronger testing volumes and favorable mix, with revenue of $2.816 billion, up 13.18% versus the prior-year period. The quarter delivered an EBITDA of $386 million and operating income of $386 million, underscoring a mid-teens margin profile (operating margin ~13.7%) despite ongoing cost pressures. Net income totaled $245 million with basic EPS of $2.18 (diluted $2.16), reflecting a positive but modest net profit expansion on a year-over-year basis (YoY net income +8.4%), tempered by a QoQ decline of roughly 12.8% in net income and a similar drop in reported earnings per share. The company continues to generate healthy operating cash flow (operating cash flow per share of $5.03) and free cash flow per share of $3.74, supporting a payout ratio of 36.3% and a modest dividend yield (~0.42%). Liquidity remains adequate (current ratio ~1.13; quick ratio ~1.04) with a lean but manageable leverage profile (debt ratio ~0.39; interest coverage ~5.6x).